#United States #San Diego #Robbins LLP #Soleno Therapeutics #SLNO stock

Robbins LLP Encourages SLNO Stockholders to Act

Robbins LLP has reached out to investors of Soleno Therapeutics, Inc. (NASDAQ: SLNO) who have experienced financial losses due to their investments in the company's stock. A class action lawsuit has been initiated for those who purchased or acquired shares in the specified period from March 26, 2025 to November 4, 2025. This legal action arises from allegations that Soleno misrepresented critical information about its Phase 3 clinical trials and the efficacy of its sole product, the diazoxide choline extended-release tablets (DCCR), used to treat hyperphagia in people affected by Prader-Willi syndrome (PWS).

Allegations Against Soleno Therapeutics

A significant aspect of the lawsuit stems from claims that the company failed to adequately disclose major safety concerns related to DCCR. Throughout the class period, investors were allegedly misled regarding the product's commercial viability and potential risks after its launch. According to the complaint, the company concealed information regarding adverse reactions linked to the treatment, including instances of excessive fluid retention that emerged during clinical trials.

An investigative report released by Scorpion Capital on August 15, 2025 detailed severe shortcomings in Soleno's clinical trial execution and raised alarms about safety and efficacy issues. Following this revelation, the stock price plummeted by approximately 12% within just two days.

Further compounding the situation, on September 10, 2025, Soleno reported a patient's death associated with DCCR, which subsequently led to a staggering 19% drop in share price over two days. The downturn continued, as further financial disclosures on November 4, 2025, revealed that the Scorpion report negatively impacted DCCR's reception within the PWS community, leading to decreased patient start forms and an increase in treatment discontinuations, resulting in an immediate 27% decline in stock price.

Shareholder Actions and Deadlines

Robbins LLP encourages all shareholders who want to take part in this lawsuit to initiate their participation before the deadline of May 5, 2026. Interested parties who wish to serve as lead plaintiffs will need to submit the requisite documentation to the court by this date. However, it’s essential to note that being part of the class action is not mandatory to qualify for financial recovery—shareholders can remain absent members if they prefer.

What to Expect from Robbins LLP

The firm operates on a contingency fee basis, meaning shareholders will incur no cost unless the case results in a financial recovery. Furthermore, Robbins LLP has built a reputation since 2002 as a leader in shareholder advocacy, focusing on helping clients recover their losses and holding corporations accountable for wrongdoing. The firm’s commitment to its clients extends to ensuring improved corporate governance and fair treatment of investors.

If you are a stockholder of Soleno Therapeutics and wish to stay updated on the lawsuit's progress or if you want to be notified of any potential settlements, please consider signing up for alerts through Stock Watch.

For more information or to participate in this class action, you can reach out by submitting a request, emailing Aaron Dumas, Jr., or calling (800) 350-6003. Don't miss your chance to take action against potential injustices perpetrated by Soleno Therapeutics, Inc.

Conclusion

In such turbulent times, it’s essential for investors to remain vigilant and informed about their investments. As legal proceedings progress, all eyes will be on the outcomes of this significant class action lawsuit led by Robbins LLP on behalf of the affected shareholders of Soleno Therapeutics. Take advantage of your rights and seek the justice you deserve.